Medtronic Appoints Top U.S. Robotic Surgeon Dr. James Porter as Chief Medical Officer for Robotic and Digital Technologies

Sep 14, 2024 00:10 CST Updated 00:10

Medtronic

Chronic Disease Medical Device and Therapy Developer

Instrument Family

Pioneer in Medical Device Media Reports

Share Professional Medical Device Knowledge

Source:Instrument Family,Reproduction without authorization is prohibited, and reproduction is allowed 24 hours later.

On September 11, Medtronic's senior management underwent another change. The frequent leadership turnover at the company this year hints at what kind of strategy and development lies ahead for this "medical device giant"?

According to the announcement, Medtronic has officially appointed a urology expert.Dr. James Porter serves as the Chief Medical Officer (CMO) for Robotics and Digital Technology in surgical operations.

This business is part of the medical surgical product portfolio——On February 1, 2023, Medtronic announced the merger of its Surgical Robotics and Surgical Innovations business units into a single Surgical Business Unit. The main core of the new business unit is Medtronic's robot-assisted surgery system, Hugo.

Dr. James Porter

According to Medtronic, Dr. Porter has extensive experience with over 5,000 robotic-assisted surgeries in the field of urology and is acclaimed as a "recognized leader" in the global surgical community. Additionally, he is alsoOne of the top robotic surgery experts in the United States, ranked among the top five nationwide.

Top Surgical Robotics Expert

Top five in the United States

Data shows,James Porter completed his residency training in urology at the University of Washington in 1996 and received specialized training in laparoscopic surgery in Heilbronn, Germany.In 2005, he joined the Swedish Medical Center in Seattle as the Director of Robotic Surgery, while also overseeing the institution's robotic and laparoscopic surgery fellowship program in the urology department. Additionally, he serves as the Director of Robotic Surgery for Providence Health Services.

Before joining the Swedish Urology Group, Dr. Porter served as the Director of Urology at Harborview Medical Center and later as the Head of the Laparoscopic and Robotic Surgery Division in the Department of Urology at the University of Washington Medical Center.

Dr. Porter focuses on treating prostate cancer, kidney cancer, and urinary system reconstructive surgery.For many years, he has made significant contributions to the field of urology, advancing several innovative surgical techniques for treating kidney tumors and testicular cancer in young men.

Dr. James Porter

Medtronic stated that Dr. Porter’s addition brings extensive clinical experience to the company, which can help further enhance its robotics and digital technology business.His ResponsibilitiesIncluding the strategic direction of managing clinical evidence programs and engaging in in-depth cooperation with doctors and all sectors of society.He will also continue to perform surgeries part-time at Providence Swedish Hospital in Seattle.

Regarding this appointment, Porter said: "My original intention of entering the medical field was to help patients. Now, being able to expand this impact globally through Medtronic is truly exciting."Tens of millions of patients worldwide still lack access to minimally invasive surgical treatments, and I look forward to collaborating with the Medtronic team to advance medical technology.

Now,Surgical procedures are rapidly evolving due to advancements in robotics and digital technology, with the Hugo and Touch Surgery platforms leading this transformation.

Accelerate the Layout of Surgical Robots

Medtronic has been continuously making efforts in the field of robotic surgery in recent years,The launched Hugo Robotic-Assisted Surgery System has become the company's representative product in the surgical robotics field and is often considered Intuitive Surgical's "most dangerous" competitor.Will become the next Da Vinci.

Hugo Robotic-Assisted Surgery System

Data shows,The Hugo system adopts a modular design, supports multi-quadrant surgical operations, and is equipped with wristed instruments, 3D visualization technology, and surgical video capture capabilities.Since its initial launch in 2019, the Hugo system has been continuously upgraded. This year, Medtronic has also added several clinical studies, planning to expand its indications toIn the field of hernia and gynecological surgery. Hugo RAS has the following four main features:

In terms of appearance, the Hugo system is equipped with four surgical arms mounted on carts, offering great flexibility.Hugo's surgical tower is equipped with Karl Storz's visualization system, and the accompanying endoscope is also of standard length, which means it can be removed from the robotic system and used as a handheld device during laparoscopic surgery.

In addition, the surgical tower is equipped with Medtronic's FT10 generator, which is specifically designed to power devices that deliver energy during robotic surgery and can also power laparoscopic and open surgical equipment.

Touch Surgery Platform

Touch Surgery

Touch Surgery is the ecosystem applied to the new generation of Hugo surgical robots.The First AI-Driven Solution.

In simple terms,This is an interactive surgical simulator designed for medical professionals.By linking the laparoscopic video port to record the entire surgical procedure, the footage is automatically uploaded to Amazon Cloud, encrypted and saved as an online-viewable surgical library, allowing users to quickly learn surgical procedures, test their knowledge, and practice.

In fact,This platform was acquired by Medtronic in 2020.In February 2020, Medtronic acquired Digital Surgery, obtained its Touch Surgery mobile application, and integrated it into the new generation of Hugo.

Surgical Robotics & Innovative Surgery

Merger of Two Major Departments

To accelerate the R&D process of its products, Medtronic has also made significant optimizations in layout and structural adjustments. Public information shows,Since 2021, Medtronic has split its business into 20 operating units and simplified its operating model to strengthen the investment portfolio and capital allocation process.。

On February 1, 2023, Medtronic underwent an internal reorganization, merging its surgical robotics and surgical innovation business units to form the Surgical Business Unit.The company said that the move aims to strengthen its position in the rapidly growing surgical market, which is expected to double in size over the next decade.

This year, Medtronic also raised its revenue growth and earnings per share (EPS) forecast for the fiscal year 2024, adjusting the organic revenue growth prediction from the previous 4.75% to a new range of 4.75% to 5%.

The latest financial report shows that this series of reforms has achieved results.Financial report data shows,In fiscal year 2024, Medtronic's total revenue reached $32.4 billion, a year-on-year increase of 3.6%, with an organic growth rate of 5.2%.

All business segments performed well, with cardiovascular business revenue reaching $11.831 billion, a year-on-year increase of 2.7%;Surgical ServicesRevenue was $8.417 billion, a year-on-year increase of 5.4%;Neuroscience revenue was $9.406 billion, an increase of 5.0% year-over-year; Diabetes revenue was $2.488 billion, an increase of 10.0% year-over-year.

Multiple Senior Executives Have Resigned Since 2024

It is worth noting that,Since 2024, multiple senior executives of Medtronic have announced their departures, involving various business units.

CFO Resignation

June 2024,Medtronic announced that Karen Parkhill will step down from her position as Executive Vice President and Chief Financial Officer of the company.Transitioned to serve as the Chief Financial Officer of HP.

According to reports,In 2023, Karen Parkhill ranked second in executive compensation at Medtronic.Second only to Medtronic Chairman and Chief Executive Officer Geoff Martha,Received a total compensation of $6.1 million (approximately RMB 44.62 million), representing a decrease of nearly 19% from the previous year.His 2023 fiscal year compensation included a base salary of $911,000 and stock and option awards totaling $5.1 million.

Karen Parkhill graduated from Southern Methodist University in the United States and later obtained a Master's degree in Accounting and Finance from the University of Chicago Booth School of Business. She joined Medtronic in June 2016 as Vice Chairman and Chief Financial Officer, and has served in this capacity for a full eight years.

Executive Vice President and Global Regional President Retires

Also in June,Medtronic Announces Rob ten Hoedt, Executive Vice President and President of Global Regions, to Retire on June 28。

It is reported that,Medtronic named ten Hoedt as one of its highest-paid executives last year, with total compensation of $5 million in the 2023 fiscal year.Meanwhile, according to the documents from the U.S. Securities and Exchange Commission (SEC),ten Hoedt is also one of the largest individual shareholders of Medtronic.As of August 2023, he held approximately 540,000 shares.

According to reports, as the president of the Global Region,ten Hoedt is fully responsible for Medtronic's product development and markets in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region.This includes the ongoing development of the Hugo surgical robot system, a project that began after Medtronic acquired Covidien in 2015 for a substantial $43 billion. Hugo received the CE mark in the European Union in 2021.

Global Vice President of Health Economics Departs

May 2024,Bonnie Handke, a 25-Year Veteran of Medtronic, Joins CVRx. Previously, she worked at MedtronicVice President of Global Health Economics, responsible for policy and reimbursement related to coronary and renal denervation, peripheral vascular health, structural heart disease, aortic and cardiac surgery.

Multiple Senior Executives Resign in March

Moreover, Medtronic, plc.Christopher Cleary, Senior Vice President of Corporate Development, after serving for 10 years, who left in March this year; also in March, the companyGastrointestinal Business President Gio Di Napoli Announces Departure; Another business unit leader of Medtronic,Ariel Mactavish, President of the Respiratory Interventions division, also announced her departure in March.

Previously, Medtronic announced plans to exit the ventilator market in February, at the same time,Bob White, Executive Vice President of Medtronic and President of the Medical Surgical Portfolio, has also left the company.

In recent years, the rapid development of technology in the medical device industry,Especially in fields such as robot-assisted surgery, digital healthcare, and minimally invasive surgery. Medtronic faces not only competitors from traditional fields but also disruptive innovations and market impacts brought by emerging technology companies.

As a leading company in the global medical device industry, MedtronicForceBold and sweeping reformsBehind isThe Company's Urgent Need for Internal Reform.At the same timeA profound consideration in addressing industry challenges, advancing technological innovation, and implementing global strategies., striving to maintain technological leadership and business flexibility in future competition while firmly seizing new opportunities in industry development.

It can be foreseen that these adjustments and strategic layouts by Medtronic will gradually reveal their far-reaching strategic significance in the coming years, driving the company toward broader globalization and continuing to lead the innovation wave in global medical technology. Medical Device Family will continue to follow up.

END

Johnson & Johnson, Doubling Down on Imaging

China's Largest Oncology Healthcare Group Enters the Medical Device Sector

Ultrasonic Scalpel Alliance Collection Imminent: How Can Chinese Brands "Overtake on a Curve"?

Optical Giant Enters the "Ophthalmic Metaverse"

The Ninth Largest Device Company: Plant Closure, Layoffs

BGI Group: Global Launch of Two Nanopore Gene Sequencers

Big Data on Imaging Equipment in China's County-Level Market (2022-2024): Who Will Take the Lead?

Annual Sales Exceed 40 Billion, Star Medical Device Recalled at Level One

Cutting 30% of Workforce in China, Is the "Giant" Accelerating Its Shift to Healthcare?

Boston Scientific: Personnel Changes

BusinessBusiness cooperation email: qxzj@landianyiliao.com